Original descriptions of Palaearctic species of the genus C. G. Thomson, 1859 (Coleoptera, Chrysomelidae, Donaciinae) and their translations.

Many original descriptions of beetles were published in Latin with specific idioms and technical terms, which are sometimes difficult to understand. The exact meaning of these descriptions is necessary for taxonomic and systematic research. Of the ten Palaearctic species regarded as valid three were described in English, the remaining seven in Latin, French, or German: Weise, 1898, (Scopoli, 1772), (Schrank, 1781), Weise, 1912, (Kunze, 1818), (Linnaeus, 1758), and (Duvivier, 1885).

Immunoprecipitation and mass spectrometry defines an extensive RBM45 protein-protein interaction network.

The pathological accumulation of RNA-binding proteins (RBPs) within inclusion bodies is a hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). RBP aggregation results in both toxic gain and loss of normal function. Determining the protein binding partners and normal functions of disease-associated RBPs is necessary to fully understand molecular mechanisms of RBPs in disease.

RBM45 homo-oligomerization mediates association with ALS-linked proteins and stress granules.

The aggregation of RNA-binding proteins is a pathological hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). RBM45 is an RNA-binding protein that forms cytoplasmic inclusions in neurons and glia in ALS and FTLD. To explore the role of RBM45 in ALS and FTLD, we examined the contribution of the protein's domains to its function, subcellular localization, and interaction with itself and ALS-linked proteins.

A Phase I study of LGD1069 in adults with advanced cancer.

LGD1069 [Targretin; 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl) propenyl] benzoic acid] is a novel synthetic retinoid X receptor-selective retinoid that has been recently identified. The goals of this study were to determine the safety, toxicity, pharmacokinetics (PKs), and metabolic profile of LGD1069 in advanced cancer patients. Sixty patients received oral LGD1069 at doses ranging from 5-1000 mg/m2/day with PK sampling performed on days 1 and 15.

Why does the central nervous system not regenerate after injury?

Spinal cord injuries in humans and in other mammals are never followed by regrowth. In recent years, considerable progress has been made in analyzing mechanisms that promote and inhibit regeneration. The focus of this review is changes that occur in the transition period in development when the central nervous system (CNS) changes from being able to regenerate to the adult state of failure.